Identifying precancerous multiple myeloma in African American adults

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The CHAAMP Internal Pilot aims to identify multiple myeloma at the precancerous stage of monoclonal gammopathy of undetermined significance (MGUS) in Black and/or African American adults aged 30 and older. Over a one-year period, participants residing in Charlotte, NC, will be screened for MGUS, with a target enrollment of 1665 individuals. Those who test positive will receive referrals for further diagnostic evaluation and may consent to a longitudinal follow-up for up to 10 years. The study seeks to reduce the risk of delayed diagnosis and improve long-term outcomes for participants.

Why it matters

Who can join: the full rules

SCREENING Inclusion Criteria:

* Age 30 years or older at the time of consent
* Either:

  1. Self-identify as Black and/or African American OR
  2. First-degree relatives (parents, siblings, or children) of patients of any race or ethnicity diagnosed with a plasma cell disorder, including MGUS, smoldering multiple myeloma (SMM), multiple myeloma (MM), solitary plasmacytoma, plasma cell leukemia, AL amyloidosis, POEMS syndrome, and Waldenström's Macroglobulinemia
* Capable and willing to provide informed consent. NOTE: HIPAA (Health Insurance Portability and Accountability Act) authorization for the release of personal health information may be included in the informed consent or obtained separately
* Reside in Charlotte, NC, or the surrounding area, based on self-report

SCREENING Exclusion Criteria:

* Self-reported history of MGUS, SMM, MM, AL amyloidosis, plasma cell leukemia, solitary plasmacytoma, Waldenstrom Macroglobulinemia, and POEMS.

LONGITUDINAL Inclusion Criteria:

* Test positive for monoclonal gammopathy during screening portion of the study
* Consent to the longitudinal portion of the study

LONGITUDINAL Exclusion Criteria:

* The participant previously underwent diagnostic work up as part of CHAAMP Internal Pilot that did not result in a diagnosis of MGUS, Smoldering Multiple Myeloma or other non-plasma cell disorder.

Where it's running

• Atrium Health Levine Cancer
  Charlotte, North Carolina, United States Recruiting

Study contacts

• Principal investigator: Manisha Bhutani, MD — Atrium Health Wake Forest Baptist Comprehensive Cancer Center
• Study coordinator: Margarita Dzhanumova
• Email: margarita.dzhanumova@atriumhealth.org
• Phone: 704-754-3768

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Multi-omics profiling to predict progression from MGUS and smoldering myeloma to symptomatic multiple myeloma

  This project will try to see if combined genomic, immune, and oral microbiome tests can predict which people with MGUS or smoldering myeloma will progress to symptomatic multiple myeloma.

  Recruiting Azienda USL Reggio Emilia - IRCCS · Bologna and 3 other locations · NCT07214324

• Sequential CAR-T therapy targeting BCMA and GPRC5D for relapsed or refractory multiple myeloma

  This will try sequential CAR-T cell therapy against BCMA and GPRC5D in people with relapsed or refractory multiple myeloma to see if it is safe and helps control the disease.

  Recruiting Phase 1/2 Essen Biotech · Beijing, Beijing Municipality · NCT07032129

• Analyzing gut microbiota in patients with monoclonal gammopathy

  This study is trying to see how the gut bacteria of people with monoclonal gammopathy differ from those without the condition to help find new ways to diagnose and treat it.

  Recruiting Zhujiang Hospital · Guanzhou, Guangdong · NCT06690593

• Early palliative care for patients with multiple myeloma and aggressive lymphoma

  This study is testing if early palliative care can improve the quality of life and comfort for people with multiple myeloma and aggressive lymphoma while they receive their usual cancer treatment.

  Recruiting University Health Network, Toronto · Toronto, Ontario · NCT06485076

• Testing linvoseltamab for eliminating abnormal plasma cells in patients with high-risk MGUS or smoldering multiple myeloma

  This study is testing if a new drug called linvoseltamab can help get rid of abnormal plasma cells in patients with high-risk MGUS or smoldering multiple myeloma.

  Recruiting at 39 sites Phase 2 Regeneron Pharmaceuticals · Baltimore, Maryland and 38 other locations · NCT06140524

• Cohort of patients with plasma cell disorders at Peking University First Hospital

  This study is looking at hospitalized patients with plasma cell disorders to see how their treatment and disease status affect their outcomes over time.

  Recruiting Peking University First Hospital · Beijing · NCT05283993

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.